Dan Shelly

Company: PolTREG

Job title: Chief Business Development Officer

Seminars:

Panel Discussion: Navigating Regulatory Interactions to Streamline the Approval Process 11:30 am

Discuss unique company experiences to provide insight into best practices Evaluating regulatory setbacks in the drug development process to accelerate successful regulatory approval Defining regulatory requirements to optimize treatment developmentRead more

day: Day 1 Treg Cell Therapy Track AM

Keynote Presentation: Leveraging Clinical Polyclonal Tregs for the Development of Modified & Engineered Tregs 9:30 am

Harnessing effective data from clinically derived polyclonal Tregs Showcasing long-term clinical Type 1 Diabetes data Utilizing polyclonal Tregs to shape the next generation of Treg therapiesRead more

day: Day Two AM

Panel Discussion: Comparing Allogeneic & Autologous Therapies: Ideal Biology Vs Real-Word Effectiveness 2:00 pm

Comparing the need for treatment availability to treatment rejection risks Reviewing therapeutic outcomes associated with both therapeutic options to identify the balance between real-world efficacy and biology Highlighting current research and emerging strategies to enhance the success of both therapy typesRead more

day: Day 1 Treg Cell Therapy Track